Original Article

Polysaccharide-Containing Macromolecules in a Kampo (Traditional Japanese Herbal) Medicine, Hochuekkito: Dual Active Ingredients for Modulation of Immune Functions on Intestinal Peyer’s Patches and Epithelial cells

Hiroaki Kiyohara,1,2 Kazuki Nonaka,1 Michiko Sekiya,1 Tsukasa Matsumoto,3 Takayuki Nagai,1,2 Yoshiaki Tabuchi,4 and Haruki Yamada1,2

1 Kitasato Institute for Life Sciences & Graduate School of Infection Control Sciences, Kitasato University, Minato-ku, Tokyo 108-8641, Japan
2 Oriental Medicine Research Center, Kitasato University, Tokyo 108-8641, Japan
3 Faculty of Pharmacy, Iwaki Meisei University, Fukushima 970-8551, Japan
4 Life Science Research Center, University of Toyama, Toyama 930-0194, Japan

Correspondence should be addressed to Haruki Yamada, yamada@lisci.kitasato-u.ac.jp

Received 11 August 2009; Accepted 19 October 2009

Copyright © 2011 Hiroaki Kiyohara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

A traditional Japanese herbal (Kampo) medicine, Hochuekkito (Bu-Zhong-Yi-Qi-Tang in Chinese, TJ-41) is a well-known Kampo formula, and has been found to enhance antigen-specific antibody response in not only local mucosal immune system in upper respiratory tract, but also systemic immune system through upper respiratory mucosal immune system. Although this immunopharmacological effect has been proposed to express by modulation of intestinal immune system including Peyer’s patches and intestinal epithelial cells, active ingredients are not known. TJ-41 directly affected the production of bone marrow cell-proliferative growth factors from murine Peyer’s patch immunocompetent cells in vitro. Among low molecular, intermediate size and macromolecular weight fractions prepared from TJ-41, only fraction containing macromolecular weight ingredients showed Peyer’s patch-mediated bone marrow cell-proliferation enhancing activity. Anion-exchange chromatography and gel filtration gave 17 subfractions comprising polysaccharides and lignins from the macromolecular weight fraction of TJ-41, and some of the subfractions showed significant enhancing activities having different degrees. Some of the subfractions also expressed stimulating activity on G-CSF-production from colonic epithelial cells, and statistically significant positive correlation was observed among enhancing activities of the subfractions against Peyer’s patch immunocompetent cells and epithelial cells. Among the fractions from TJ-41 oral administration of macromolecular weight ingredient fraction to mice succeeded to enhance antigen-specific antibody response in systemic immune system through upper respiratory mucosal immune system, but all the separated fractions failed to enhance the in vivo antibody response in upper respiratory tract.

1. Introduction

A formula of traditional Japanese herbal (Kampo) medicine, Hochuekkito (Bu-Zong-Yi-Qi-Tang in Chinese, TJ-41) comprises 10 kinds of single herbs, and has been used traditionally for the treatment of weak patients, who have chronic diseases possessing symptoms such as loss of appetite, mild fever, night sweat, palpitation, fear, restlessness, weak feeble voice, slurred speech and disturbance of vision [1]. The medicine is intended to be applied for patients bearing the symptoms in respiratory apparatus [2], and given clinical efficacies for treatments of chronic cold, prevention of respiratory infection with MRSA on patient having impaired consciousness [3], prevention of respiratory infection after surgery [4], and improvement of chronic obstructive pulmonary disease (COPD) [5, 6] on modern medical care in Japan.

In upper respiratory tract, specified local mucosal immune system exists, and nasal immunization with antigen induces antigen-specific plasmablasts in nasal-associated lymphoreticular tissue (NALT) [7]. The plasmablasts migrate into systemic blood stream through jugular lymphatic trunk,
and are mainly distributed into spleen and peripheral lymph nodes as systemic immune system in addition to lamina propria of upper respiratory mucosal immune system due to interaction between several homing receptors and their ligands for lymphocytes [7–9]. Finally, antigen-specific antibody forming (plasma) cells are produced in these local immune systems [7, 8]. Recently, we have found that TJ-41 enhances not only antigen-specific secretory IgA antibody production in upper respiratory mucosal immune system, but also antigen-specific immunoglobulin (IgG) production in systemic immune system against nasal immunization with antigen [10]. This immunopharmacological effect of TJ-41 was abrogated by impairment of intestinal immune system by oral administration of methotrexate [10]. Intestinal mucosal immune system includes Peyer’s patches and isolated lymphoid follicles (ILF) as the specialized secondary lymphoid organs [7]. These lymphoid organs play as inductive sites for mucosal immune system, and B and T lymphocytes migrate from the organs through mesenteric lymph node and thoracic duct to the other local mucosal immune system including upper respiratory mucosal immune system and systemic immune system [7, 11]. Matsumoto et al. [12] have found that TJ-41 also enhances antigen-specific antibody response against oral immunization in not only intestine but also serum and nasal cavity. It also has been clarified that proportion of CD62L-positive B lymphocytes in Peyer’s patches and blood stream significantly increased by oral administration of TJ-41 to mice [12]. These facts postulates that active ingredient(s) in TJ-41 interact with immunocompetent cells in Peyer’s patches to modulate homing receptor expression and/or cytokine production, resulting in the stimulation of upper respiratory mucosal immune system through certain bystander effects of lymphocytes that are recruited from intestinal immune system. Therefore, it is believed that Peyer’s patches are one of first target organs for expression of stimulating activity of TJ-41 on upper respiratory and intestinal mucosal immune systems.

Meanwhile, intestinal lumen are covered by numerous epithelial cells, and the cells also have been clarified to play roles as inductive site of mucosal immune system through expressions of MHC class I and II, some adhesive molecules like VCAM-1, and several cytokines to crosstalk with underlying lymphocytes and dendritic cells in lamina 

**Figure 1:** Chemical profile of TJ-41 analyzed by 3D HPLC. Each peak of TJ-41 in the HPLC profile was identified by comparison of the retention times and UV spectra of chemically defined standard compounds. HPLC condition was as follows: Column; Tosoh TSK GEL ODS-80Ts (4.6 × 250 mm). Carrier A: 0.05 M ammonium acetate (pH 3.6). Carrier B: acetonitrile. Gradient: 10%–100% carrier B linear in 60 min. Flow rate: 1.0 mL min⁻¹. Injection volume: 30 micro liter. Detector: Shimadzu SPD-M10A VP.
Immunomodulating activity against Peyer’s patch immunocompetent cells (relative fluorescence units)

![Graph comparing immunomodulating activities of TJ-41 and TJ-48 against Peyer’s patch immunocompetent cells.](image)

**Figure 2**: Comparison of immunomodulating activities of TJ-41 and TJ-48 against Peyer’s patch immunocompetent cells. Peyer’s patch cells from early aged C3H/HeJ mice (6-months old) were cultured in 96-well culture plate with 10, 100, or 200 μg mL⁻¹ of TJ-41 or TJ-48 for 6 days, and then bone marrow cells from young C3H/HeJ mice were further cultured with the culture supernatant of Peyer’s patch cells. Relative amounts of hemopoietic growth factor in the culture supernatants of Peyer’s patch cells were estimated as number of proliferated bone marrow cells, which were measured by Alamar Blue method. Data were expressed as mean ± SD (n = 4), and analyzed by ANOVA followed by post hoc analysis using Scheffe’s test. ALR-5IIa-1-1 is a β-d-(1 → 3,6)-galactan-containing polysaccharide as positive control described previously [17].

propria [13, 14]. Dendritic cells in lamina propria migrate into mesenteric lymph nodes, and the resulting cells interact with both lymphocytes and dendritic cells that are recruited from Peyer’s patches, then lymphocytes in mesenteric lymph nodes are circulated to populate mucosal and systemic immune systems through thoracic duct [11, 15]. TJ-41 has been shown to enhance G-CSF production of both murine normal colonic epithelial cell-line (MCE301) and primary-cultured murine colonic epithelial cells [16]. Therefore, it is hypothesized that active ingredients in TJ-41 interact with both epithelial cells and immunocompetent cells in Peyer’s patches, and resulting to potentiate distal mucosal and systemic immune systems by migration of functionally modulated lymphocytes through mesenteric lymph nodes from Peyer’s patches. Although it has been proposed that macromolecular weight ingredients may contribute to expression of G-CSF production enhancing activity against epithelial cells [16], the active ingredients in TJ-41 for modulation of Peyer’s patch immunocompetent cells are not known.

This article deals with clarification of active ingredients in TJ-41 for modulation of immunocompetent cells in Peyer’s patches, and polysaccharide-containing macromolecular ingredients in TJ-41 were found to be dual active ingredients for Peyer’s patch cells and intestinal epithelial cells.

2. Methods

2.1. Materials. Spray-dried extract preparation of Ho-chuekkito (Bu-Zhong-Yi-Qi-Tang in Chinese, TJ-41, batch no. 920041001PO) was kindly supplied from Tsumura & Co. (Tokyo, Japan). For the preparation of TJ-41, a mixture of Astragalus Radix (4 g, roots of Astragalus membranaceus Bunge), Atractylodis lanceae Rhizoma (4 g, rhizomes of Atractylodes lancea DC.), Ginseng Radix (4 g, roots of Panax ginseng C.A. Meyer), Angelicae Radix (3 g, roots
Evidence-Based Complementary and Alternative Medicine

**Figure 4:** Effect of chemical and enzymic treatments of F-2 (a) and F-5 (b) on the immunomodulating activity against Peyer’s patch immunocompetent cells of F-2 and F-5. Peyer’s patch cells from early aged C3H/HeJ mice (6 months old) were cultured in 96-well culture plate with 50 or 100 μg/mL of periodate, chlorite or amylase treated F-2 (a) or F-5 (b) for 6 days, and then bone marrow cells from young C3H/HeJ mice (7 weeks old) were further cultured with the culture supernatant of Peyer’s patch cells. Relative amounts of hemopoietic growth factor in the culture supernatants of Peyer’s patch cells were estimated as number of proliferated bone marrow cells, which were measured by Alamar Blue method. Data were expressed as mean ± SD (n = 4), and analyzed by ANOVA followed by post hoc analysis using Scheffé’s test. ALR-5IIa-1-1 is a β-d-(1→3,6)-galactan-containing polysaccharide as positive control described previously [17].

**Table 1:** Chemical properties of F-2 and F-5 and their chemical and enzymatic treated products.

| Component          | F-2 Carbohydrate content (%) | F-2 Uronic acid content (%) | F-2 Protein content (%) | F-2 Component sugar (mol.%) |
|--------------------|------------------------------|----------------------------|-------------------------|-----------------------------|
|                    | F-2 Amylase digested         | F-2 Periodate oxidized     | F-2 Chlorite treated    | F-5 Amylase digested        |
| Carbohydrate content (%) | 65.2                        | 36.5                       | 19.2                    | 101.8                       |
| Uronic acid content (%)   | 7.3                         | 14.4                       | 3.6                     | 8.2                         |
| Protein content (%)       | 4.1                         | 10.8                       | 26.4                    | 11.6                        |
| Component sugar (mol.%)  |                            | n.d.                      | n.d.                    | 2.2                         |
| Arabinose              | 3.4                         | 9.9                       | n.d.                    | 10.8                        |
| Rhamnose               | 0.5                         | 1.4                       | n.d.                    | 16.3                        |
| Fucose                 | 0.1                         | 0.6                       | n.d.                    | 3.0                         |
| Xylose                 | 1.0                         | 1.8                       | n.d.                    | 16.3                        |
| Glucuronic acid        | 0.6                         | trace                     | trace                   | 11.6                        |
| Galacturonic acid      | 5.5                         | 48.0                      | 70.4                    | 6.8                         |
| Mannose                | trace                       | 5.0                       | 3.2                     | 1.0                         |
| Galactose              | 2.1                         | 12.6                      | 13.1                    | 2.7                         |
| Glucose                | 86.9                        | 20.9                      | 13.4                    | 5.7                         |

*Not detected.
with 285 mL of water by heating at 100 °C (0.5 g, rhizomes of Zingiber Cimicifuga simplex of uralensis Fisch Markovich), Glycyrrhizae Radix (1.5 g, roots of Citrus unshu Pericarpium (2 g, pericarps of ripe fruits of Angelica acutiloba Kitagawa), Bupleuri Radix (2 g, roots of Bupleurum falcatum L.), Zizyphi Fructus (2 g, fruits of Zizyphus jujuba Miller var. inermis Rehder), Aurantii Bobilis Pericarpium (2 g, pericarps of ripe fruits of Citrus unshu Markovich), Glycyrrhizae Radix (1.5 g, roots of Glycyrrhiza uralensis Fisch et DC.), Cimicifugae Rhiiza (1 g, rhizomes of Cimicifuga simplex Wormskjord) and Zingiberis Rhizoma (0.5 g, rhizomes of Zingiber officinale Roscoe) was extracted with 285 mL of water by heating at 100°C for 1 h. The extracted solution was filtered and spray-dried to obtain dry extract powder (TJ-41, 5 g). Three-dimensional high performance liquid chromatography (HPLC) analysis was carried out to know chemical profile of TJ-41, and the spray-dried extract preparation of TJ-41 showing 3D-HPLC profile as in Figure 1 was used for the present study. Spray-dried extract preparation of Juzentaihoto (Shi-Quan-Da-Bu-Tang, Tsumura & Co. as described previously [10]. Arabino-3,6-galactan (ALR-5IIa-1-1), which has immunomodulating activity against Peyer’s patch cells, was purified as a positive control from rhizomes of Atractylodes lancea according to the procedure of Yu et al. [17].

2.2. Cells. Establishment and characterization of murine normal colonic epithelial cell-line MCE301 were reported previously [18]. The MCE301 cells were cultured according to the procedure of Matsumoto et al. [16].

2.3. Animals. Specific pathogen-free female C3H/HeJ and BALB/c mice of 7 weeks old (young) and 6 months old (early aged) were purchased from Japan SLC (Shizuoka, Japan). The animals were housed in plastic gages in an air-conditioned room at 23 ± 2°C with a relative humidity of 55 ± 10% under a 12-h light–dark cycle, fed a standard laboratory diet and given water ad libitum. Animal experiments were approved by the Animal Research Committee of Kitasato University, and performed in accordance with Guidelines for Care and Use of Laboratory Animal at Kitasato University and the National Research Council Guide for the Care and Use of Laboratory Animals in Japan.

2.4. Analytical Methods. The carbohydrate, uronic acid and protein contents were determined by phenol-H2SO4 method [19], m-hydroxybiphenyl method [20] and Bradford method [21], respectively, using galactose, galacturonic acid and bovine immunoglobulin as the respective standards. Lignin contents were analyzed by acetyl bromide method [22]. Component sugars were analyzed as TMS methylglycoside derivatives [23] by GC on Hewlett-Packard Model 5890 series II gas chromatograph as described previously [16].

2.5. Fractionation of TJ-41. TJ-41 (100 g) was fractionated into five fractions; MeOH-soluble fraction (F-1, yield 73.3%), MeOH and water-insoluble fraction (F-2, yield 9.9%), dialyzable intermediate size ingredient fraction (F-3, yield 4.8%) and non-dialyzable intermediate size ingredient fraction (F-4, yield 0.2%), and macromolecular weight ingredient fraction (F-5, yield 7.7%) according to the method described previously [16].

2.6. Periodate Oxidation of F-2 and F-5 from TJ-41. Periodate oxidation was performed by the procedure as described previously [16].

2.7. Amylase Digestion of F-2 and F-5 from TJ-41. Amylase digestion was performed as described previously [16].

2.8. Chlorite Treatment of F-2 and F-5 from TJ-41. Solutions of F-2 and F-5 (1 g each) in 4% acetic acid (500 mL) were each added sodium chlorite (5 g), and incubated at 70°C for 40 min. The reaction mixtures were neutralized with 3 M NaOH, and then dialyzed against distilled water for 4 days. The non-dialyzable portions were concentrated by evaporation, and lyophilized to obtain chlorite-treated F-2 (yield 78.2%) and F-5 (yield 75.5%).

2.9. Purification of Polysaccharides and Lignin-Polysaccharide Complexes from F-5

2.9.1. Anion-Exchange Chromatography. A solution of F-5 (2.6 g) in 300 mL of distilled water was applied to a DEAE-Sepharose FF column (HCO3−), GE Healthcare Japan, 5.5 × 25 cm), and a neutral fraction (F-5I, 1.15 g, yield from F-5; 44.5%) was obtained by washing with distilled water. Absorbed fractions were eluted gradually with 50, 100, 200, 300, 400, 500, 600 mM and 1 M NH4HCO3 in a stepwise manner, and each eluate was dialyzed and lyophilized.
to obtain eight fractions; F-5IIa (50 mM NH₄HCO₃, 210 mg, yield from F-5; 8.1%), F-5IIb (100 mM NH₄HCO₃, 56 mg, 2.2%), F-5IIc (200 mM NH₄HCO₃, 249 mg, 9.6%), F-5IIId (300 mM NH₄HCO₃, 97.3 mg, 3.8%), F-5IIle (400 mM NH₄HCO₃, 478 mg, 18.5%), F-5IIIf (500 mM NH₄HCO₃, 38 mg, 1.5%), F-5IIlg (600 mM NH₄HCO₃, 6 mg, 0.2%), and F-5IIlh (1 M NH₄HCO₃, 19 mg, 0.7%).

2.9.2. Gel Filtration. All acidic fractions, obtained from F-5 by anion-exchange chromatography except F-5IIg (because of too small amount available), were individually fractionated on a Sephacryl S-200 column (2.6 × 93 cm) with 0.2 M NaCl. All the resulting subfractions were dialyzed against distilled water, and lyophilized to give 17 different polysaccharide-containing fractions (PS1–PS17).

2.10. Measurement of In Vitro Immunomodulating Activity against Peyer’s Patch Immunocompetent Cells. Immunomodulating activity was measured by enhanced production of bone marrow cells-proliferative cytokines from Peyer’s patch.
immunocompetent cells of 7 weeks old female C3H/HeJ mice according to Hong et al. [24].

2.11. Measurement of G-CSF Production Enhancing Activity on MCE301 Cells. The procedure was performed in accordance with the method described previously [16].

2.12. Measurement of In Vivo Immunomodulating Activity of Fractions from TJ-41 on Upper Respiratory Mucosal Immune System. The procedures were carried out according to the method described previously [10]. Briefly, young or early aged BALB/c mice were immunized twice with a primary and secondary intranasal inoculations of 5 μg of a split vaccine of influenza hemagglutinin (influenza A/NC/20 HA vaccine) (kind gift from Center for Biologicals of The Kitasato Institute) at Days 0 and 28. The mice were administered orally aqueous solutions of TJ-41 (100 mg kg\(^{-1}\) day\(^{-1}\)) or each fraction (F-1 (73.3 mg kg\(^{-1}\) day\(^{-1}\)), F-2 (9.9 mg kg\(^{-1}\) day\(^{-1}\)), F-3 (4.8 mg kg\(^{-1}\) day\(^{-1}\)), F-4 (0.2 mg kg\(^{-1}\) day\(^{-1}\)) and F-5 (7.7 mg kg\(^{-1}\) day\(^{-1}\)) (doses were calculated by the yields of the respective fractions from TJ-41) from 7 days before the primary immunization (Day-7) to Day 42 once a day. The sera were prepared from blood samples of the mice at Day 42, and then nasal washes were taken from the posterior opening of the nasopharynx by injection with sterilized phosphate buffered saline containing 0.1% bovine serum albumin. The titers of influenza virus-specific IgG antibody (in sera) and IgA antibody (in nasal washes) were measured by ELISA according to the procedure as described previously [10].

2.13. Statistics. Data were expressed as mean ± SD, and differences between groups were analyzed by analysis of variance (ANOVA) followed by post hoc analyses using Scheffe’s test. The probability (P) values < .05 were considered significant.

Figure 7: Immunomodulating activities against Peyer’s patch immunocompetent cells and intestinal epithelial cells of polysaccharide-containing subfractions obtained from macromolecular weight ingredient fraction (F-5) of TJ-41. (a) Immunomodulating activities against Peyer’s patch immunocompetent cells of the subfractions obtained from Figure 6. Peyer’s patch cells from early aged C3H/HeJ mice (6 months old) were cultured in 96-well culture plate with 100 μg mL\(^{-1}\) of the subfractions for 6 days, and then bone marrow cells from young C3H/HeJ mice (7 weeks old) were further cultured with the culture supernatant of Peyer’s patch cells. Relative amounts of hemopoietic growth factor in the culture supernatants of Peyer’s patch cells were estimated as number of proliferated bone marrow cells, which were measured by Alamar Blue method. (b) IL-6 production enhancing activity on Peyer’s patch immunocompetent cells of the subfractions from Figure 6. Peyer’s patch cells from early aged C3H/HeJ mice (6 months old) were cultured in 96-well culture plate with 100 μg mL\(^{-1}\) of the subfractions for 6 days, and IL-6 content in the culture supernatant was measured using an ELISA. (c) G-CSF production enhancing activity on intestinal epithelial cells of the subfractions from Figure 6. Murine colonic epithelial cell line, MCE301 cells were cultured for 48 h in 96-well culture plate with 0.5 μg mL\(^{-1}\) of the subfractions, and G-CSF content in the culture supernatant was measured using an ELISA. All data were expressed as mean ± SD (n = 4), and analyzed by ANOVA followed by post hoc analysis using Scheffe’s test.
### Table 2: Chemical properties of subfractions obtained from macromolecular weight fraction (F-5) of TJ-41.

|       | Carbohydrate content (%) | Uronic acid content (%) | Protein content (%) | Lignin content | Component sugar (mol. %) | Mannose (%) | Galactose (%) | Glucose (%) |
|-------|---------------------------|-------------------------|---------------------|----------------|---------------------------|-------------|---------------|-------------|
| PS1   | 72.8                      | 13.3                    | 7.5                 | 9.1            | Arabinose 41.5, Rhamnose 1.1, Fucose 0.3, Xylose 5.7, Glucuronic acid 0.8, Galacturonic acid n.d. | 2.0         | 43.0          | 5.6         |
| PS2   | 115.9                     | 14.5                    | 11.5                | 10.3           | Arabinose 7.9, Rhamnose 1.3, Fucose 0.3, Xylose 7.1, Glucuronic acid 0.5, Galacturonic acid 3.8 | 11.9        | 8.5           | 56.8        |
| PS3   | 89.0                      | 19.3                    | 7.5                 | 11.3           | Arabinose 41.1, Rhamnose 2.5, Fucose 0.2, Xylose 5.7, Glucuronic acid 2.1, Galacturonic acid 0.5 | 1.5         | 45.0          | 1.4         |
| PS4   | 73.8                      | 10.7                    | 10.7                | 13.0           | Arabinose 34.5, Rhamnose 4.8, Fucose 0.4, Xylose 11.1, Glucuronic acid 2.3, Galacturonic acid 1.9 | 6.8         | 32.8          | 5.2         |
| PS5   | 83.2                      | 16.2                    | 7.8                 | 6.2            | Arabinose 40.8, Rhamnose 6.1, Fucose 0.3, Xylose 5.1, Glucuronic acid 4.9, Galacturonic acid 8.4 | 2.6         | 15.0          | 16.7        |
| PS6   | 24.9                      | 21.4                    | 18.7                | 14.9           | Arabinose 16.4, Rhamnose 7.4, Fucose 1.1, Xylose 2.1, Glucuronic acid 3.0, Galacturonic acid 41.1 | 6.9         | 6.5           | 15.5        |
| PS7   | 37.9                      | 24.3                    | 7.3                 | 7.4            | Arabinose 26.8, Rhamnose 7.9, Fucose 0.5, Xylose 2.8, Glucuronic acid 3.5, Galacturonic acid 37.0 | n.d.        | 6.9           | 14.7        |
| PS8   | 28.5                      | 49.6                    | 10.5                | 14.6           | Arabinose 14.1, Rhamnose 5.4, Fucose 0.8, Xylose 2.2, Glucuronic acid 1.1, Galacturonic acid 66.6 | n.d.        | 2.8           | 7.0         |
| PS9   | 6.7                       | 60.6                    | 11.8                | 21.1           | Arabinose 4.7, Rhamnose 1.8, Fucose 0.5, Xylose 1.4, Glucuronic acid 4.9, Galacturonic acid 73.4 | n.d.        | 2.4           | 10.9        |
| PS10  | 38.7                      | 28.4                    | 14.1                | 9.1            | Arabinose 14.7, Rhamnose 4.0, Fucose 0.7, Xylose 2.1, Glucuronic acid 7.9, Galacturonic acid 61.2 | n.d.        | 3.2           | 6.3         |
| PS11  | 29.7                      | 78.6                    | 15.6                | 10.9           | Arabinose 7.8, Rhamnose 2.3, Fucose 0.7, Xylose 1.3, Glucuronic acid 3.0, Galacturonic acid 74.7 | n.d.        | 3.4           | 6.8         |
| PS12  | 26.7                      | 62.7                    | 17.3                | 20.1           | Arabinose 9.1, Rhamnose 2.8, Fucose 0.8, Xylose 1.5, Glucuronic acid 6.2, Galacturonic acid 62.3 | 3.7         | 3.3           | 10.3        |
| PS13  | 34.3                      | 67.9                    | 16.3                | 16.4           | Arabinose 16.6, Rhamnose 4.8, Fucose 0.7, Xylose 2.3, Glucuronic acid 3.8, Galacturonic acid 41.2 | 10.8        | 10.2          | 9.6         |
| PS14  | 17.9                      | 43.0                    | 20.2                | 32.1           | Arabinose 10.0, Rhamnose 3.3, Fucose 0.9, Xylose 2.3, Glucuronic acid 3.1, Galacturonic acid 44.3 | 15.8        | 6.1           | 14.2        |
| PS15  | 27.1                      | 28.8                    | 22.5                | 16.4           | Arabinose 18.9, Rhamnose 4.2, Fucose 0.4, Xylose 3.5, Glucuronic acid 4.3, Galacturonic acid 18.6 | 15.2        | 19.6          | 15.2        |
| PS16  | 22.7                      | 14.9                    | 25.8                | 21.1           | Arabinose 18.0, Rhamnose 3.7, Fucose 0.5, Xylose 5.7, Glucuronic acid 7.6, Galacturonic acid 19.3 | 15.2        | 9.2           | 20.3        |
| PS17  | 11.7                      | 20.5                    | 17.6                | 36.2           | Arabinose 13.7, Rhamnose 6.0, Fucose 0.7, Xylose 4.6, Glucuronic acid 4.2, Galacturonic acid 23.7 | 19.2        | 5.6           | 22.4        |

*Bradford method has been reported to cross react with lignin [25]. Therefore the values of protein contents did not indicate exact contents of protein in the subfractions.

n.d., Not detected.
3. Results

3.1. Evaluation of Immunomodulating Activity of TJ-41 against Peyer’s Patch Immunocompetent Cells. In order to analyze whether TJ-41 is able to modulate directly functions of immunocompetent cells in Peyer’s patches, after Peyer’s patch cells from early aged (6 months old) C3H/HeJ mice were cultured with TJ-41 for 6 days, bone marrow cells from young (7 weeks old) C3H/HeJ mice were further cultured with the culture supernatant of Peyer’s patch cells, and then relative amounts of hemopoietic growth factors in the culture supernatant produced from Peyer’s patch cells were estimated as number of the proliferated bone marrow cells. The numbers of proliferated bone marrow cells significantly increased when Peyer’s patch cells were cultured with TJ-41 (Figure 2). The degree of the enhancement was same as those when Peyer’s patch cells were cultured with Juzentaihojito (TJ-48), which has been reported to have immunomodulating activity against Peyer’s patch cells [24] (Figure 2).

3.2. Analysis of Active Ingredients for Immunomodulation of Peyer’s Patch Immunocompetent Cells. In order to elucidate which ingredient in TJ-41 contributes to expression of immunomodulating activity against Peyer’s patch immunocompetent cells, TJ-41 was roughly fractionated by MeOH extraction, water extraction, EtOH precipitation and dialysis to obtain MeOH-soluble fraction (F-1), MeOH- and water-insoluble fraction (F-2), MeOH-insoluble and dialyzable fraction as dialyzable intermediate size ingredient fraction (F-3), EtOH-soluble and non-dialyzable fraction as non-dialyzable intermediate size ingredient fraction (F-4), and macromolecular weight ingredient fraction (F-5) [16]. When these five fractions were tested for immunomodulating activity against Peyer’s patch cells, F-2 and F-5 showed statistically significant activity, but not the other fractions (Figure 3). Both F-2 and F-5 consisted mainly of carbohydrate (Table 1), and periodate oxidation, which is capable to degrade carbohydrate moieties, significantly decreased activities of both F-2 and F-5 (Figure 4). Because F-2 and F-5 mainly comprised glucose as a component sugar (Table 1), suggesting the presence of starch-like polysaccharide in these fractions, both fractions were also digested with α- and β-amylases. Amylase digestion did not reduce activities of both F-2 and F-5 (Figure 4). Component sugar analyses indicated that the amylase-digested F-2 and F-5 reduced contents of glucose significantly, and consisted mainly of galacturonic acid in addition to notable proportions of arabinose and galactose (Table 1). When F-2 and F-5 each were treated with sodium chlorite in order to destroy lignin molecules, the reaction products reduced the activity, but the considerable activity still remained for both F-2 and F-5 (Figure 4). These results suggested that F-2 and F-5 contained polysaccharides and/or lignin-polysaccharide complexes as active ingredients, and it was assumed that these active macromolecules in TJ-41 were separately fractionated into F-2 (water-insoluble fraction) and F-5 (water-soluble fraction) depending on their solubility in water.

F-5 was further fractionated by anion-exchange chromatography on a DEAE-Sepharose FF column (HCO$_3^-$) and one neutral (F-5I) and 8 acidic fractions (F-5IIa–F-5IIh) were obtained (Figure 5). All acidic fractions consisted of arabinose, galactose, glucose and/or galacturonic acid whereas the neutral fraction (F-5I) mainly comprised glucose (data not shown). Although F-5I did not show immunomodulating activity against Peyer’s patch cells, all acidic fractions had significant activity (data not shown). Therefore, the acidic fractions were further fractionated by gel filtration except F-5Ilg because of too small amount available. By gel filtration on a Sephacryl S-200 column, F-5IIa, IIIc, IId, and IIf each gave two subfractions (PS1 and PS2 (from F-5IIa), PS6 and PS7 (from F-5IIc), PS8 and PS9 (from F-5IId), and PS13 and PS14 (from F-5IIf)), which were rich in carbohydrate (Figure 6). Whereas, F-5IIb, IIe and IIh gave three carbohydrate-rich subfractions each (PS3, PS4, and PS5 (from F-5IIb), PS10, PS11, and PS12 (from F-5IIe), and PS15, PS16, and PS17 (from F-5IIh)). Analyses of chemical properties indicated that PS1, PS2, PS3, PS4, PS5, PS11, PS12, and PS17 contained <60% of carbohydrate. All subfractions contained different amount of lignin, especially, PS5, PS8, PS9, PS10, and PS14 comprised about 60–70% of carbohydrate (Table 2). Meanwhile, PS6, PS15, PS16, and PS17 contained over 80% of carbohydrate (total of carbohydrate and uronic acid contents in Table 2), whereas PS7, PS8, PS9, PS10, and PS14 comprised about 60–70% of carbohydrate (Table 2). Meanwhile, PS6, PS15, PS16, and PS17 contained over 80% of carbohydrate (total of carbohydrate and uronic acid contents in Table 2), whereas PS7, PS8, PS9, PS10, and PS14 comprised about 60–70% of carbohydrate (Table 2). Meanwhile, PS6, PS15, PS16, and PS17 contained over 80% of carbohydrate (total of carbohydrate and uronic acid contents in Table 2), whereas PS7, PS8, PS9, PS10, and PS14 comprised about 60–70% of carbohydrate (Table 2). Meanwhile, PS6, PS15, PS16, and PS17 contained over 80% of carbohydrate (total of carbohydrate and uronic acid contents in Table 2), whereas PS7, PS8, PS9, PS10, and PS14 comprised about 60–70% of carbohydrate (Table 2).
mRNA expression of interleukin-6 (IL-6) on Peyer’s patch immunocompetent cells (data not shown), the effect of these subfractions on production of IL-6 from Peyer’s patch cells were also evaluated. As shown in Figure 7(b), PS6, PS12, PS13, PS14, PS15, PS16 and PS17 significantly enhanced IL-6 production from Peyer’s patch cells.

3.3. Evaluation of Modulating Activity of Polysaccharide-Containing Macromolecules from TJ-41 on G-CSF Production of Intestinal Epithelial Cells. Previous study has indicated that TJ-41 enhances de novo G-CSF synthesis on the murine colonic epithelial cell line, MCE301, and that only macromolecular weight ingredient fraction (F-5) of TJ-41 has G-CSF production enhancing activity on MCE301 [16]. Therefore, PS1–PS17 obtained from F-5 in the present study were also analyzed effects on G-CSF production of MCE301. As shown in Figure 7(c), PS2, PS5, PS6, PS7, PS11 and PS12–PS17 significantly enhanced G-CSF production at a concentration of 0.5 μg mL⁻¹. Simple linear regression analysis was performed between degrees of immunomodulating activity against Peyer’s patch cells and G-CSF production enhancing activity on MCE301 cells of these subfractions. The statistically significant positive correlation (γ = 0.68559, \( P < .01, n = 17 \)) between both activities was observed (Figure 8), and suggesting that these subfractions modulate functions of not only Peyer’s patch immunocompetent cells but also intestinal epithelial cells.

3.4. Contribution of Polysaccharide-Containing Macromolecules for Immunomodulating Activity of TJ-41 on Upper Respiratory Mucosal Immune System. It has been found that oral administration of TJ-41 stimulates antigen-specific antibody production on only systemic immune system against nasally inoculated antigen to the young mice (7 weeks old) [10], whereas TJ-41 enhances antibody production on upper respiratory tract of early aged mice (6 months old) [10]. In order to evaluate whether polysaccharide-containing macromolecules in TJ-41 contribute to expression of enhancing activity on upper respiratory mucosal immune system of TJ-41, each of F-1–F-5 obtained from TJ-41, was orally administered at doses related to their yields from TJ-41 to young or early aged BALB/c mice, which were nasally immunized twice with influenza vaccine, and titers of influenza virus specific IgG or IgA antibody...
were measured for sera or nasal washes from the mice, respectively. Oral administrations of F-1, F-2, F-3, and F-4 failed to increase influenza virus specific IgG antibody titer in sera of young mice, whereas F-5 significantly enhanced the antibody titer as same as TJ-41 (Figure 9(a)). However, when these fractions each were administered to early aged mice, all fractions did not enhance influenza virus specific IgA antibody titer in nasal cavity even though TJ-41 could (Figure 9(b)).

4. Discussion

In previous study TJ-41 has been found to potentiate antibody response in upper respiratory mucosal immune system in vivo but not another Kampo formula, TJ-48, and it has been suggested that TJ-41 express this stimulating activity through intestinal immune system [10]. The present study indicated that TJ-41 directly modulated immunocompetent cells in Peyer’s patches to enhance production of bone marrow cell-proliferative growth factors in vitro. However, significant difference could not be observed between TJ-41 and TJ-48. When mRNA expressions of cytokines were analyzed by PCR using cells which were cultured with either TJ-41 or TJ-48 for 6 days, enhanced mRNA expressions of IL-2, IL-5, IL-6, IL-10 and TGF-β were observed in cultured Peyer’s patch cells with TJ-41 compared with those in cells cultured without the formula (Kiyohara & Nonaka, unpublished data). Meanwhile, TJ-48 significantly enhanced mRNA expression of only IL-2 (Kiyohara & Nonaka, unpublished data). These results postulated that TJ-41 might modulate cytokine productions in different manner from TJ-48. The difference may bring to one of reasons why TJ-41 can potentiate upper respiratory mucosal immune system. It is necessary to analyze how TJ-41 and TJ-48 differently modulate cytokine production on immunocompetent cells in Peyer’s patches in vivo in future study.

Numerous ingredients are considered to be present in TJ-41 because this multiherb formula consists of 10 kinds of component herbs. The present study indicated that macromolecular weight ingredients in F-5 were responsible active ingredients for immunomodulation of Peyer’s patch immunocompetent cells. All macromolecular weight ingredients in TJ-41 comprised various proportions of polysaccharides and lignins. Polysaccharides and lignins are primary metabolites, and lignins are generally conjugated with poly- and oligosaccharides to form lignin-polysaccharide complexes in plant cell walls [25, 26]. The present study suggests that both structural moieties are required for expression of modulating activity on Peyer’s patch cells because the activity was significantly reduced by both periodate oxidation and chlorite treatment. However, no correlation was observed between lignin contents and degrees of the immunomodulating activity on Peyer’s patch cells of 17 subfractions, and it is assumed that detailed structural parts of both lignin and polysaccharide moieties may participate to expression of the immunomodulating activity. We have already found a immunomodulating polysaccharide (ALR-5IIa-1-1 used as a positive control in the present study) against Peyer’s patch cells from Atractylodes lancea as one of component herbs of TJ-41 [17], and this polysaccharide was shown to express the activity through β-d-(1→3,6)-galactan moiety as the active carbohydrate sequence [27]. Although ALR-5IIa-1-1 clearly decreased the activity by an enzymatic degradation of β-d-(1→3,6)-galactan moiety [27],
the immunomodulating activity against Peyer’s patch cells of some of the fractions obtained from F-5 of TJ-41 could not be reduced by the same enzymatic degradation for β-d-(1 → 3,6)-galactan moiety (Kiyohara & Sekiya, unpublished data). These results assumed that the active polysaccharides and lignin-polysaccharide complexes in TJ-41 have different responsible structures from ALR-5IIa-1-1 for expression of the activity.

Intestinal epithelial cells sit at interface between lumen and lymphocyte-rich lamina propria. The epithelial cells function as effector/regulator cells of a host’s immune response to foreign substances including various pathogens and food antigens [13, 14]. Matsumoto et al. have suggested that certain ingredients in F-5 of TJ-41 contribute to express G-CSF production enhancing activity on intestinal epithelial cells [16]. A question arises whether Peyer’s patch cells-modulating polysaccharides and/or lignin-polysaccharide complexes, isolated from TJ-41 in the present study, also have enhancing activity on G-CSF production of intestinal epithelial cells. Correlation analysis strongly suggests that immunomodulating polysaccharides and/or lignin-polysaccharide complexes against Peyer’s patch cells in TJ-41 also interact with intestinal epithelial cells to affect on their immunological functions. This proposes that polysaccharides and/or lignin-polysaccharide complexes play as dual active ingredients for immunomodulation of immunocompetent cells in Peyer’s patches and intestinal epithelial cells. It has been reported that carbohydrate moiety of polysaccharide and/or lignin-polysaccharide complexes in F-5 participate to enhancing activity of G-CSF production of intestinal epithelial cells [16]. However, structural features of the responsible carbohydrate moiety in the subfractions from F-5 also could not be analyzed in the present study, and further study needs to be carried out for clarification of responsible structures for immunomodulation of intestinal epithelial cells and immunocompetent cells in Peyer’s patches.

Another question arises whether only macromolecular weight ingredients in TJ-41 behave as responsible molecules for expression of stimulating activity on upper respiratory mucosal immune system of TJ-41. The present study indicated that oral administration of only polysaccharides and/or lignin-polysaccharide complexes in F-5 potentiates antibody response against nasal inoculated antigen in systemic immune system. Antibody response against nasal immunization in systemic immune system is known to be induced as a result of migration of antigen-specific lymphocytes from NALT to spleen and peripheral lymph nodes [7–9]. Parts of naive and activated lymphocytes in Peyer’s patches are generally considered to migrate into spleen and peripheral lymph nodes to interact with lymphocytes which are recruited from NALT [11]. Therefore it is hypothesized that antigen-specific antibody productions in spleen and peripheral lymph nodes may be enhanced by interaction between lymphocytes from NALT and Peyer’s patch lymphocytes which were functionally modulated by the actions of polysaccharides/lignin-polysaccharide complexes of TJ-41. Since the possibility that these macromolecular weight ingredients directly enhance systemic immune system after their absorption from digestive system is not ruled out, detailed mechanism for this stimulatory effect is necessary to investigate by further study.

The present study indicated that not only macromolecular weight ingredients (F-5) but also other ingredients (F-1, F-2, F-3, and F-4) of TJ-41 could not stimulate antibody response in upper respiratory tract against nasal immunization unlike TJ-41. This result strongly postulates that stimulation of upper respiratory mucosal immune system by the action of TJ-41 may be expressed by contributions of numerous ingredients in the fractions, F-1 to F-5 of TJ-41. It is generally known that lymphocytes are recruited to upper respiratory mucosal immune system from both hemopoietic system and Peyer’s patches to control the immune system [7–9]. Process of lymphocyte homing from Peyer’s patches to upper respiratory mucosal immune system is regulated by many molecules: (i) adhesive molecules like CD62L (L-selectin) and integrin α4β1, and chemokine receptors (CCR7 and CCR10) on lymphocytes, (ii) ligands for adhesion molecules like 6-sulfosialy LewisX-expressing glycoprotein (PNAd) and VCAM-1, and chemokine like CCL28 on high endothelial venule (HEV) in upper respiratory tract [7–9]. It is difficult to consider that macromolecular weight ingredients of TJ-41 modulate expression of all above homing-related molecules. Therefore, it is hypothesized that TJ-41 may contain some other active ingredients, which can modulate expression of these homing-related molecules in addition to polysaccharides/lignin-polysaccharides, which modulate functions of immunocompetent cells in Peyer’s patches and intestinal epithelial cells (Figure 10). Further study concerning with clarification of modulating ingredients on expression of homing-related molecules in TJ-41 may lead us to understand detailed mechanism for immunomodulation of upper respiratory mucosal immune system by the action of TJ-41.

Acknowledgments

The authors thank Dr. I. Sakakibara (Research Division, Tsumura & Co.) and Tsumura & Co. for 3D-HPLC analysis of TJ-41. Ministry of Education, Culture, Sports, Science and Technology of Japan, and Grants-in Aid for Scientific Research (B and C) from Japan Society for the Promotion of Science (grant ID: 16390201 and 21590772) and The Uehara Memorial Foundation.

References

[1] K. Terasawa, Kampo Japanese-Oriental Medicine: Insight from Clinical Case, KK Standard McIntyre, Tokyo, Japan, 1993.
[2] T. Hanawa, Series of Contemporary Medicine 20: Lesson of Clinical Practice for Kampo Medicine, Kinbara, Tokyo, Japan, 1995.
[3] M. Kitahara and S. Ishikawa, “Prevention of infection with MRSA by Hochu-ekki-to in patients with protracted consciousness disorder,” Biotherapy, vol. 16, no. 3, pp. 261–263, 2002.
[4] M. Kitahara and K. Seki, “Investigation of effects of Japanese herbal (Kampo) medicines on infection in patients with
protracted consciousness disorder,” *Prog Med*, vol. 19, pp. 996–999, 1999.

[5] Y. Sugiyama, “Effect of Hochu-ekki-to on chronic obstructive pulmonary disease,” *Pharma Medica*, vol. 25, pp. 31–33, 2007.

[6] Y. Fukuti, “COPD as systemic illness: efficacy of Hochuekkito,” *Geriatric Medical*, vol. 46, pp. 263–266, 2008.

[7] H. Kiyono and S. Fukuyama, “Nalt-versus Peyer’s-patch-mediated mucosal immunity,” *Nature Reviews Immunology*, vol. 4, no. 9, pp. 699–710, 2004.

[8] T. Sminia and G. Kraal, “Nasal-associated lymphoid tissue,” in *Mucosal Immunology*, P. L. Ogra, J. Mestecky, M. E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee, Eds., pp. 357–364, Academic Press, London, UK, 2nd edition, 1999.

[9] P. Brandtzæg and F.-E. Johansen, “Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties,” *Immunological Reviews*, vol. 206, pp. 32–63, 2005.

[10] H. Kiyohara, T. Nagai, K. Munakata et al., “Stimulating effect of Japanese herbal (Kampo) medicine, Hochuekkito on upper respiratory mucosal immune system,” *Evidence-Based Complementary and Alternative Medicine*, vol. 3, no. 4, pp. 459–467, 2006.

[11] A. J. Macpherson and K. Smith, “Mesenteric lymph node at the center of immune anatomy,” *Journal of Experimental Medicine*, vol. 203, no. 3, pp. 497–500, 2005.

[12] T. Matsumoto, M. Noguchi, O. Hayashi, K. Makino, and H. Yamada, “Hochuekkito, a Kampo (traditional Japanese herbal) medicine, enhances mucosal IgA antibody response in mice immunized with antigen-entrapped biodegradable microparticles,” *Evidence-Based Complementary and Alternative Medicine*, vol. 7, no. 1, pp. 69–77, 2010.

[13] L. Shao, O. Kamalu, and L. Mayer, “Non-classical MHC class I molecules on intestinal epithelial cells: mediators of mucosal crosstalk,” *Immunological Reviews*, vol. 206, pp. 160–176, 2005.

[14] I. P. Oswald, “Role of intestinal epithelial cells in the innate immune defence of the pig intestine,” *Veterinary Research*, vol. 37, no. 3, pp. 359–368, 2006.

[15] B. L. Kelsall and F. Leon, “Involvement of intestinal dendritic cells in oral tolerance, immunity to pathogens, and inflammatory bowel disease,” *Immunological Reviews*, vol. 206, pp. 132–148, 2005.

[16] T. Matsumoto, M. Moriya, H. Kiyohara, Y. Tabuchi, and H. Yamada, “Hochuekkito, a Kampo (traditional Japanese herbal) medicine, and its polysaccharide portion stimulate G-CSF secretion from intestinal epithelial cells,” *Wireless Networks*, vol. 7, no. 3, pp. 331–340, 2010.

[17] K.-W. Yu, H. Kiyohara, T. Matsumoto, H.-C. Yang, and H. Yamada, “Intestinal immune system modulating polysaccharides from rhizomes of Atractylodes lancea DC,” *Carbohydrate Research*, vol. 339, pp. 763–770, 2004.

[18] Y. Tabuchi, S. Ohta, Y. Arat et al., “Establishment and characterization of a colonic epithelial cell line MCE301 from transgenic mice harboring temperature-sensitive simian virus 40 large T-antigen gene,” *Cell Structure and Function*, vol. 25, no. 5, pp. 297–307, 2000.

[19] M. Dubois, K. A. Gilles, J. K. Hamilton, P. A. Rebers, and F. Smith, “Colorimetric method for determination of sugars and related substances,” *Analytical Chemistry*, vol. 28, no. 3, pp. 350–356, 1956.

[20] N. Blumenkrantz and G. Asboe Hansen, “New method for quantitative determination of uronic acids,” *Analytical Biochemistry*, vol. 54, no. 2, pp. 484–489, 1973.